Abstract
Data from randomized clinical trials have shown the safety and efficacy of the XIENCE V in selected populations. However, limited data are available comparing the XIENCE V to the first-generation CYPHER sirolimus-eluting stent. This study aimed to assess the long-term safety and clinical efficacy of the XIENCE V everolimus-eluting stent compared to first-generation stents in an unselected patient population. This retrospective analysis included 6,069 patients treated with CYPHER, TAXUS, and XIENCE stents from 2003 to 2009 at our institution. The patients were followed up for ≥1 year after the index procedure. The baseline characteristics were generally comparable among the 3 groups, with the exception of a significantly greater prevalence of diabetes mellitus, systemic hypertension, and a history of angioplasty and coronary bypass surgery among the XIENCE patients. The XIENCE patients also had a twofold greater rate of type C lesions. One-year follow-up data were available for 82% of the patients. The 1-year major adverse cardiovascular events rate was 9.3% for the XIENCE stent versus 9.8% for the CYPHER stent and 11.5% for the TAXUS stent (p = 0.11). Mortality was lower in the XIENCE group than in the CYPHER and TAXUS groups (...Continue Reading
References
Jul 1, 1994·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·R GuidoinJ Awad
Oct 3, 2003·The New England Journal of Medicine·Jeffrey W MosesUNKNOWN SIRIUS Investigators
Apr 14, 2004·Circulation·Gregg W StoneUNKNOWN TAXUS-IV Investigators
Dec 7, 2007·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Hana Vaknin-AssaRan Kornowski
Jan 28, 2009·Circulation·Gregg W StoneUNKNOWN SPIRIT III Investigators
Jul 15, 2009·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Nicolas W ShammasMatthew Winter
Jan 12, 2010·Lancet·Elvin KedhiPieter Cornelis Smits
Feb 5, 2010·JACC. Cardiovascular Interventions·Scot GargUNKNOWN SPIRIT II Investigators
May 7, 2010·The New England Journal of Medicine·Gregg W StoneUNKNOWN SPIRIT IV Investigators
Citations
Nov 8, 2013·BMJ : British Medical Journal·Eliano P NavareseElvin Kedhi
Feb 12, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jessica A LyndonNick Birbilis
Nov 10, 2013·Cardiovascular Intervention and Therapeutics·Masa-aki KawashiriMasakazu Yamagishi
Feb 19, 2014·Expert Opinion on Drug Delivery·Ricardo O EscárcegaRon Waksman
Mar 7, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Minoru IchikawaYoshiyuki Kijima
Feb 1, 2013·Journal of Interventional Cardiology·Kishore J HarjaiJudy Boura
May 16, 2015·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Hideaki OtaRon Waksman
Oct 31, 2013·International Journal of Cardiology·Joshua P LohRon Waksman
Apr 15, 2015·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Hideaki OtaRon Waksman
Nov 24, 2012·JACC. Cardiovascular Interventions·Ron Waksman, Israel M Barbash
Feb 10, 2019·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Yuhei NojimaShinsuke Nanto
Dec 8, 2019·Scientific Reports·Haijun ZhangJunbo Ge
May 10, 2020·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Yusuke WatanabeAntonio Colombo
Nov 10, 2020·Circulation Journal : Official Journal of the Japanese Circulation Society·Takero MatsuuraGaku Nakazawa
Jun 3, 2021·Materials·Alexandru Scafa UdrișteElisabeta Bădilă